By Alexander Bueso
Date: Friday 06 Jan 2023
LONDON (ShareCast) - (Sharecast News) - The People's Republic of China is negotiating license rights for Pfizer's antiviral drug Paxlovid.
If successful, that would allow domestic Chinese pharmaceutical companies to manufacture and distribute a generic version of the drug, Reuters reported citing three sources.
Beijing's aim was to have a deal in place before the Lunar New Year on 22 January, one source reportedly said.
-- More to follow --
Email this article to a friend
or share it with one of these popular networks:
Currency | US Dollars |
Share Price | $ 29.09 |
Change Today | $ 0.12 |
% Change | 0.41 % |
52 Week High | $33.94 |
52 Week Low | $25.26 |
Volume | 25,013,039 |
Shares Issued | 5,646m |
Market Cap | $164,242m |
Beta | 0.18 |
RiskGrade | 102 |
Strong Buy | 3 |
Buy | 6 |
Neutral | 15 |
Sell | 0 |
Strong Sell | 0 |
Total | 24 |
Time | Volume / Share Price |
16:02 | 2,861,250 @ $29.09 |
15:59 | 174 @ $29.09 |
15:59 | 100 @ $29.09 |
15:59 | 100 @ $29.11 |
15:59 | 100 @ $29.11 |
You are here: research